February 8, 2014

Bascom Palmer Eye Institute

Sponsored by the University of Miami Miller School of Medicine
Bascom Palmer Eye Institute invites you to join us in February 2014 for our eleventh annual angiogenesis meeting. This unique and exciting symposium entitled *Angiogenesis, Exudation, and Degeneration 2014* will be held February 8, 2014 at the Mandarin Oriental Hotel in Miami, Florida.

The meeting will feature an exceptional gathering of basic scientists, clinicians, and healthcare experts, all focused on understanding and treating neovascular and exudative diseases of the eye. The meeting will highlight the revolutionary pharmacotherapies now in development and clinical practice for the management of neovascular AMD, macular edema, diabetic retinopathy, and retinopathy of prematurity with a special emphasis on the present and future financial impact of these drugs on clinical practices and Medicare.
COURSE DESCRIPTION
Angiogenesis 2014 follows the tradition of excellence established by the widely acclaimed Angiogenesis programs between 2004 and 2014. Designed for retinal specialists, general ophthalmologists and researchers, the current program will review the latest therapies for exudative eye diseases and the use of these new treatments in clinical practice. We will emphasize current and future treatments for a broad spectrum of retinal diseases with special emphasis on age-related macular degeneration and diabetic retinopathy.

COURSE OBJECTIVES
Upon completion of this program, participants should be able to:

- Enhance patient care by evaluating the current global use of anti-VEGF drugs for exudative ocular diseases
- Manage patients with anti-VEGF therapy through the preferred dosing practices
- Improve management skills by evaluating all the risks associated with injections of anti-VEGF drugs
- Analyze results of clinical trials in exudative macular diseases and apply to clinical practice
- Evaluate the benefits and limitations of combination therapies for exudative diseases
- Evaluate the benefits and limitations of different imaging strategies for age-related macular degeneration
- Enhance patient care by analyzing the genetic basis for different macular and retinal degenerative conditions
- Analyze the rationale for emerging treatments for different macular and retinal degenerative conditions
- Identify the types of stem cells and appreciate how they will be used to treat macular diseases
<table>
<thead>
<tr>
<th>Time</th>
<th>Session/Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:00 am</td>
<td>Registration and Continental Breakfast</td>
</tr>
<tr>
<td>7:55</td>
<td>Welcome and Overview</td>
</tr>
<tr>
<td></td>
<td><em>Philip J. Rosenfeld, MD, PhD, Harry W. Flynn, Jr., MD, and Carmen A. Puliafito, MD, MBA</em></td>
</tr>
<tr>
<td>8:00</td>
<td>SESSION I – Dry Age-Related Macular Degeneration</td>
</tr>
<tr>
<td></td>
<td>Common and Rare Genetics of Macular Degeneration 2014: Paths to Treatment</td>
</tr>
<tr>
<td></td>
<td><em>Johanna M. Seddon, MD, SCM</em></td>
</tr>
<tr>
<td>8:10</td>
<td>Toward a Refined Understanding of Genotype-Phenotype Associations in Age-related Macular Degeneration</td>
</tr>
<tr>
<td></td>
<td><em>Gregory S. Hageman, PhD</em></td>
</tr>
<tr>
<td>8:20</td>
<td>Rehabilitating Lipofuscin as a Marker of RPE Health: Laboratory Autofluorescence Insights</td>
</tr>
<tr>
<td></td>
<td><em>Christine A. Curcio, PhD, FARVO</em></td>
</tr>
<tr>
<td>8:30</td>
<td>AREDS2 Update</td>
</tr>
<tr>
<td></td>
<td><em>Emily Y. Chew, MD</em></td>
</tr>
<tr>
<td>8:40</td>
<td>Two Color Microperimetry as an Endpoint for Dry Age-Related Macular Degeneration Trials: Present Status</td>
</tr>
<tr>
<td></td>
<td><em>Karl G. Csaky, MD, PhD</em></td>
</tr>
<tr>
<td>8:50</td>
<td>Preclinical and Initial Clinic Results of Idebenone, A Ubiquinone Analog for Dry AMD</td>
</tr>
<tr>
<td></td>
<td><em>Scott W. Cousins, MD</em></td>
</tr>
<tr>
<td>9:00</td>
<td>Membrane Attack Complex (MAC), Protectin (CD59) and AMD</td>
</tr>
<tr>
<td></td>
<td><em>Elias Reichel, MD</em></td>
</tr>
<tr>
<td>9:10</td>
<td>Anti-Factor D Therapy for Atrophic AMD: Phase II Clinical Trial Results</td>
</tr>
<tr>
<td></td>
<td><em>Carl D. Regillo, MD, FACS</em></td>
</tr>
<tr>
<td>10:00</td>
<td>SESSION II: Stem Cells for Retinal Diseases</td>
</tr>
<tr>
<td></td>
<td>Application of iP S Cells to Retinal Diseases</td>
</tr>
<tr>
<td></td>
<td><em>Masayo Takahashi, MD, PhD</em></td>
</tr>
<tr>
<td>10:00</td>
<td>Microcatheter Delivery of Cell Therapy CNTO 2476 for Atrophic Age Related Macular Degeneration</td>
</tr>
<tr>
<td></td>
<td><em>Allen C. Ho, MD</em></td>
</tr>
<tr>
<td>10:10</td>
<td>hysterectomy Delivery of Cell Therapy CNTO 2476 for Atrophic Age Related Macular Degeneration</td>
</tr>
<tr>
<td>10:20</td>
<td>h-ESC Derived RPE Transplantation for Atrophic AMD</td>
</tr>
<tr>
<td></td>
<td><em>Ninel Z. Gregori, MD</em></td>
</tr>
<tr>
<td>10:30</td>
<td>The California Project to Cure Blindness – An Update</td>
</tr>
<tr>
<td></td>
<td><em>David R. Hinton, MD, FARVO</em></td>
</tr>
<tr>
<td>10:40</td>
<td>Subretinal Transplantation of Human Central Nervous System Stem Cells (HuCNS-SC) for the Treatment of Geographic Atrophy: Scientific Rationale and Study Design</td>
</tr>
<tr>
<td></td>
<td><em>Theodore Leng, MD, MS</em></td>
</tr>
<tr>
<td>10:50</td>
<td>MEMBRANE ATTACK COMPLEX (MAC), PROTECTIN (CD59) AND AMD</td>
</tr>
<tr>
<td></td>
<td><em>Elias Reichel, MD</em></td>
</tr>
<tr>
<td>11:00</td>
<td>Anti-Factor D Therapy for Atrophic AMD: Phase II Clinical Trial Results</td>
</tr>
<tr>
<td></td>
<td><em>Carl D. Regillo, MD, FACS</em></td>
</tr>
<tr>
<td>11:10</td>
<td>Application of iP S Cells to Retinal Diseases</td>
</tr>
<tr>
<td></td>
<td><em>Masayo Takahashi, MD, PhD</em></td>
</tr>
<tr>
<td>11:20</td>
<td>h-ESC Derived RPE Transplantation for Atrophic AMD</td>
</tr>
<tr>
<td></td>
<td><em>Ninel Z. Gregori, MD</em></td>
</tr>
<tr>
<td>11:30</td>
<td>The California Project to Cure Blindness – An Update</td>
</tr>
<tr>
<td></td>
<td><em>David R. Hinton, MD, FARVO</em></td>
</tr>
<tr>
<td>11:40</td>
<td>Subretinal Transplantation of Human Central Nervous System Stem Cells (HuCNS-SC) for the Treatment of Geographic Atrophy: Scientific Rationale and Study Design</td>
</tr>
<tr>
<td></td>
<td><em>Theodore Leng, MD, MS</em></td>
</tr>
<tr>
<td>11:50</td>
<td>Microcatheter Delivery of Cell Therapy CNTO 2476 for Atrophic Age Related Macular Degeneration</td>
</tr>
<tr>
<td></td>
<td><em>Allen C. Ho, MD</em></td>
</tr>
<tr>
<td>12:00</td>
<td>Microcatheter Delivery of Cell Therapy CNTO 2476 for Atrophic Age Related Macular Degeneration</td>
</tr>
<tr>
<td>12:10</td>
<td>MEMBRANE ATTACK COMPLEX (MAC), PROTECTIN (CD59) AND AMD</td>
</tr>
<tr>
<td></td>
<td><em>Elias Reichel, MD</em></td>
</tr>
<tr>
<td>12:20</td>
<td>Anti-Factor D Therapy for Atrophic AMD: Phase II Clinical Trial Results</td>
</tr>
<tr>
<td></td>
<td><em>Carl D. Regillo, MD, FACS</em></td>
</tr>
<tr>
<td>12:30</td>
<td>Application of iP S Cells to Retinal Diseases</td>
</tr>
<tr>
<td></td>
<td><em>Masayo Takahashi, MD, PhD</em></td>
</tr>
<tr>
<td>12:40</td>
<td>h-ESC Derived RPE Transplantation for Atrophic AMD</td>
</tr>
<tr>
<td></td>
<td><em>Ninel Z. Gregori, MD</em></td>
</tr>
<tr>
<td>12:50</td>
<td>The California Project to Cure Blindness – An Update</td>
</tr>
<tr>
<td></td>
<td><em>David R. Hinton, MD, FARVO</em></td>
</tr>
<tr>
<td>1:00</td>
<td>Subretinal Transplantation of Human Central Nervous System Stem Cells (HuCNS-SC) for the Treatment of Geographic Atrophy: Scientific Rationale and Study Design</td>
</tr>
<tr>
<td></td>
<td><em>Theodore Leng, MD, MS</em></td>
</tr>
<tr>
<td>1:10</td>
<td>Microcatheter Delivery of Cell Therapy CNTO 2476 for Atrophic Age Related Macular Degeneration</td>
</tr>
<tr>
<td></td>
<td><em>Allen C. Ho, MD</em></td>
</tr>
</tbody>
</table>
10:10 The London Project - RPE Sheets for AMD
Lyndon da Cruz, MD, MA, FRACO, FRCOphth, PhD

10:20 Stem Cell Based 3D Printing of Retina
Kang Zhang, MD, PhD

SESSION III – Neovascular AMD: Conbercept Phase III Results
Moderator: Philip J. Rosenfeld, MD, PhD

10:30 Conbercept Development and Clinical Trials
Peter K. Kaiser, MD

10:45 Treating Neovascular AMD by Using Conbercept: Preliminary Results from AURORA & PHOENIX Studies
Xiaoxin Li, MD

11:00 Imaging Data from the Phase 3 Clinical Trial of Conbercept in Neovascular AMD
Ronald P. Danis, MD

11:15 Q&A/Discussion

SESSION IV – Neovascular AMD

11:25 CATT and Beyond
Daniel F. Martin, MD

11:40 IVAN and Beyond
Usha Chakravarthy, MD

11:55 Effect of Early, Persistent Macular Fluid on Visual Acuity in Wet AMD: Subgroup Analyses of the VIEW 1 VIEW 2 Studies
Philip J. Rosenfeld MD, PhD

12:05 pm Does Anti-VEGF Therapy Promote Geographic Atrophy in Exudative AMD?
Jason S. Slakter, MD

12:15 Dry Retinal Volume: Predicting Outcomes after Pharmacotherapy
Srinivas R. Sadda, MD

12:25 Systemic Safety of Anti-VEGF Therapy
Robert L. Avery, MD

12:35 Lunch

SESSION IV – Neovascular AMD (continued)

1:20 Clinicopathologic Correlation of Eyes with Streptococcal Endophthalmitis Following Intravitreal Injections
Sander R. Dubovy, MD

1:30 The Role of Genetics in Response to Anti-VEGF Therapy in Wet AMD
Jaclyn L. Kovach, MD
1:40 Immunoglobulins for CNV: Are Generics Just as Good?  
Jayakrishna Ambati, MD

1:50 Pre-Clinical Investigations of Intravitreal Zaltrap  
Michel E. Farah, MD

2:00 Results of the ROLL Study: Conversion of PEDs from 2mg Ranibizumab to 2mg Aflibercept  
Anne E. Fung, MD

2:10 Change in PED Volume Following the Switch from Bevacizumab/Ranibizumab to Aflibercept  
Mariana R. Thorell, MD

2:20 Update on Encapsulated Cell Technology for Wet AMD  
Glenn J. Jaffe, MD

2:30 Oral Anti-VEGF Therapy for Wet AMD  
David M. Brown, MD, FACS

2:40 Anti-VEGF Gene Therapy: Early Clinical Results  
Using the Ocular Biofactory in Wet AMD  
Thomas W. Chalberg, PhD

2:50 Morphologic Correlation of Visual Outcome with Anti-PDGF Combination Treatment in Exudative AMD  
Pravin U. Dugel, MD

3:00 Stereotactic X-ray Radiotherapy for Neovascular AMD  
Darius M. Moshfeghi, MD

3:10 Update on Treatment with Squalamine Eye Drops  
Lawrence J. Singerman, MD, FACS, FICS

3:20 Integrin Antagonism in AMD and DME  
Hugo Quiroz-Mercado, MD

3:30 Inhibitor of Differentiation (Id) Proteins and Genes: A New Target for the Treatment of Posterior Segment Neovascularization  
Glenn L. Stoller, MD, FACS

3:40 Current Clinical Trials for Hereditary Chorioretinal Degenerations  
Byron L. Lam, MD

3:50 Multiple Evanescent White Dot Syndrome: Multimodal Imaging  
Lawrence A. Yannuzzi, MD

4:00 A New, International Classification System and the Role of Ocriplasmin for Diseases of the Vitreomacular Interface  
Jay S. Duker, MD
4:10 Ocriplasmin Safety and Side Effects
Baruch D. Kuppermann, MD, PhD

4:20 Update on the MacTel Project and the Lowy Medical Research Institute: From Bench to Bedside in 8 Years
Martin Friedlander, MD, PhD

4:30 Intravitreal Aflibercept for Macular Edema Due to Branch Retinal Vein Occlusion: 24 Week Results of the VIBRANT Study
Jeffrey S. Heier, MD

4:40 Update on Aflibercept for Diabetic Macular Edema
Diana V. Do, MD

4:50 Dexamethasone Intravitreal Implant for Diabetes: Result of the Phase 3 Trials
David S. Boyer, MD

5:00 Update on the DRCR Network Studies
Harry W. Flynn, Jr., MD

5:10 Treatment of Diabetic Macular Edema by Tie2 Activation with an Inhibitor of Vascular Endothelial-Protein Tyrosine Phosphatase
Peter A. Campochiaro, MD

5:20 Interleukin-1-beta Inhibition in Proliferative Diabetic Retinopathy: Interim Analysis of a Clinical Pilot Study
Stephan Michels, MD, MBA

5:30 Additional Pharmacologic Agents in Development for Diabetic Macular Edema
Quan Dong Nguyen, MD, MSc

5:40 Non-Visible Non-Lethal Photocoagulation for Treatment of Macular Edema Employing the Arrhenius Calculation
Mark S. Blumenkranz, MD

5:50 Peripheral Diabetic Retinopathy Diagnoses and Management
Michael T. Trese, MD

6:00 Adjourn/Cocktail Reception
Bascom Palmer Eye Institute
Angiogenesis, Exudation, and Degeneration 2014

Saturday, February 8, 2014
Registration is limited, so please register early.

Last Name / First Name (as you want it to appear on name badge) / Degree

Last Four Digits of Social Security Number (for record keeping purposes only)

Specialty / Sub-specialty

Affiliated Institution

Address (Check box if new address)

City/State

Country / Zip or Postal Code

Office phone Office fax

Email

REGISTRATION: $425

Enclosed is my check made payable to Bascom Palmer Eye Institute—Angiogenesis 2014

Please bill my credit card:

☐ Mastercard ☐ Visa ☐ American Express

Card number

Security code Expiration date Billing zip code

Name on card

Signature

By fax: Please complete this registration form with your credit card payment and fax to (305) 326-6518. By mail: Please complete this registration form and return with your check or credit card payment to: Bascom Palmer Eye Institute Continuing Medical Education Department 1120 NW 14th Street, Suite 1558 Miami, FL 33136 (Attn: Karen Davila)
Lyndon da Cruz, MD, MA, FRACO, FRCOphth, PhD
Consultant Ophthalmic Surgeon
Moorefields Eye Hospital
London, England

Ronald P. Danis, MD
Professor of Ophthalmology
Director, UW-Madison Fundus Photograph Reading Center
University of Wisconsin
Madison, WI

Diana V. Do, MD
Vice Chair for Education
Director of the Carl Camras Center for Innovative Clinical Trials in Ophthalmology
St. Mary’s Truhlsen Eye Institute
University of Nebraska Medical Center
Omaha, NE

Sander R. Dubovy, MD
Professor of Ophthalmology
Bascom Palmer Eye Institute
University of Miami Miller School of Medicine
Miami, FL

Pravin U. Dugel, MD
Clinical Associate Professor of Ophthalmology
Keck School of Medicine
University of Southern California
Los Angeles, CA
Managing Partner
Retina Consultants of Arizona
Phoenix, AZ

Jay S. Duker, MD
Professor and Chairman
Director, New England Eye Center
Tufts Medical Center
Tufts University School of Medicine
Boston, MA

Michel E. Farah, MD
Professor of Ophthalmology
President, Vision Institute
Paulista School of Medicine
São Paulo Federal University
São Paulo, Brazil

Martin Friedlander, MD, PhD
Professor, Department of Cell and Molecular Biology
Chief, Retina Services, Division of Ophthalmology, Department of Surgery
The Scripps Research Institute
Scripps Clinic
La Jolla, CA

Anne E. Fung, MD
California Pacific Medical Center
Pacific Eye Associates
San Francisco, CA

Ninel Z. Gregori, MD
Associate Professor of Clinical Ophthalmology
Bascom Palmer Eye Institute
University of Miami Miller School of Medicine
Miami, FL

Gregory S. Hageman, PhD
John A. Moran Presidential Professor
Executive Director, Moran Center for Translational Medicine
John A. Moran Eye Center
University of Utah
Salt Lake City, UT

Jeffrey S. Heier, MD
Director, Vitreo-Retina Service
Ophthalmic Consultants of Boston
Boston, MA

David R. Hinton, MD, FARVO
Professor of Pathology and Ophthalmology
Gavin S. Herbert Professor of Retinal Research
Associate Dean of Vision Science
Vice Chair, Department of Pathology
Keck School of Medicine
University of Southern California
Los Angeles, CA

Lyndon da Cruz, MD, MA, FRACO, FRCOphth, PhD
Consultant Ophthalmic Surgeon
Moorefields Eye Hospital
London, England

Ronald P. Danis, MD
Professor of Ophthalmology
Director, UW-Madison Fundus Photograph Reading Center
University of Wisconsin
Madison, WI

Diana V. Do, MD
Vice Chair for Education
Director of the Carl Camras Center for Innovative Clinical Trials in Ophthalmology
St. Mary’s Truhlsen Eye Institute
University of Nebraska Medical Center
Omaha, NE

Sander R. Dubovy, MD
Professor of Ophthalmology
Bascom Palmer Eye Institute
University of Miami Miller School of Medicine
Miami, FL

Pravin U. Dugel, MD
Clinical Associate Professor of Ophthalmology
Keck School of Medicine
University of Southern California
Los Angeles, CA
Managing Partner
Retina Consultants of Arizona
Phoenix, AZ

Jay S. Duker, MD
Professor and Chairman
Director, New England Eye Center
Tufts Medical Center
Tufts University School of Medicine
Boston, MA

Michel E. Farah, MD
Professor of Ophthalmology
President, Vision Institute
Paulista School of Medicine
São Paulo Federal University
São Paulo, Brazil

Martin Friedlander, MD, PhD
Professor, Department of Cell and Molecular Biology
Chief, Retina Services, Division of Ophthalmology, Department of Surgery
The Scripps Research Institute
Scripps Clinic
La Jolla, CA

Anne E. Fung, MD
California Pacific Medical Center
Pacific Eye Associates
San Francisco, CA

Ninel Z. Gregori, MD
Associate Professor of Clinical Ophthalmology
Bascom Palmer Eye Institute
University of Miami Miller School of Medicine
Miami, FL

Gregory S. Hageman, PhD
John A. Moran Presidential Professor
Executive Director, Moran Center for Translational Medicine
John A. Moran Eye Center
University of Utah
Salt Lake City, UT

Jeffrey S. Heier, MD
Director, Vitreo-Retina Service
Ophthalmic Consultants of Boston
Boston, MA

David R. Hinton, MD, FARVO
Professor of Pathology and Ophthalmology
Gavin S. Herbert Professor of Retinal Research
Associate Dean of Vision Science
Vice Chair, Department of Pathology
Keck School of Medicine
University of Southern California
Los Angeles, CA

Lyndon da Cruz, MD, MA, FRACO, FRCOphth, PhD
Consultant Ophthalmic Surgeon
Moorefields Eye Hospital
London, England

Ronald P. Danis, MD
Professor of Ophthalmology
Director, UW-Madison Fundus Photograph Reading Center
University of Wisconsin
Madison, WI

Diana V. Do, MD
Vice Chair for Education
Director of the Carl Camras Center for Innovative Clinical Trials in Ophthalmology
St. Mary’s Truhlsen Eye Institute
University of Nebraska Medical Center
Omaha, NE

Sander R. Dubovy, MD
Professor of Ophthalmology
Bascom Palmer Eye Institute
University of Miami Miller School of Medicine
Miami, FL

Pravin U. Dugel, MD
Clinical Associate Professor of Ophthalmology
Keck School of Medicine
University of Southern California
Los Angeles, CA
Managing Partner
Retina Consultants of Arizona
Phoenix, AZ

Jay S. Duker, MD
Professor and Chairman
Director, New England Eye Center
Tufts Medical Center
Tufts University School of Medicine
Boston, MA

Michel E. Farah, MD
Professor of Ophthalmology
President, Vision Institute
Paulista School of Medicine
São Paulo Federal University
São Paulo, Brazil

Martin Friedlander, MD, PhD
Professor, Department of Cell and Molecular Biology
Chief, Retina Services, Division of Ophthalmology, Department of Surgery
The Scripps Research Institute
Scripps Clinic
La Jolla, CA

Anne E. Fung, MD
California Pacific Medical Center
Pacific Eye Associates
San Francisco, CA

Ninel Z. Gregori, MD
Associate Professor of Clinical Ophthalmology
Bascom Palmer Eye Institute
University of Miami Miller School of Medicine
Miami, FL

Gregory S. Hageman, PhD
John A. Moran Presidential Professor
Executive Director, Moran Center for Translational Medicine
John A. Moran Eye Center
University of Utah
Salt Lake City, UT

Jeffrey S. Heier, MD
Director, Vitreo-Retina Service
Ophthalmic Consultants of Boston
Boston, MA

David R. Hinton, MD, FARVO
Professor of Pathology and Ophthalmology
Gavin S. Herbert Professor of Retinal Research
Associate Dean of Vision Science
Vice Chair, Department of Pathology
Keck School of Medicine
University of Southern California
Los Angeles, CA

Lyndon da Cruz, MD, MA, FRACO, FRCOphth, PhD
Consultant Ophthalmic Surgeon
Moorefields Eye Hospital
London, England

Ronald P. Danis, MD
Professor of Ophthalmology
Director, UW-Madison Fundus Photograph Reading Center
University of Wisconsin
Madison, WI

Diana V. Do, MD
Vice Chair for Education
Director of the Carl Camras Center for Innovative Clinical Trials in Ophthalmology
St. Mary’s Truhlsen Eye Institute
University of Nebraska Medical Center
Omaha, NE

Sander R. Dubovy, MD
Professor of Ophthalmology
Bascom Palmer Eye Institute
University of Miami Miller School of Medicine
Miami, FL

Pravin U. Dugel, MD
Clinical Associate Professor of Ophthalmology
Keck School of Medicine
University of Southern California
Los Angeles, CA
Managing Partner
Retina Consultants of Arizona
Phoenix, AZ

Jay S. Duker, MD
Professor and Chairman
Director, New England Eye Center
Tufts Medical Center
Tufts University School of Medicine
Boston, MA

Michel E. Farah, MD
Professor of Ophthalmology
President, Vision Institute
Paulista School of Medicine
São Paulo Federal University
São Paulo, Brazil

Martin Friedlander, MD, PhD
Professor, Department of Cell and Molecular Biology
Chief, Retina Services, Division of Ophthalmology, Department of Surgery
The Scripps Research Institute
Scripps Clinic
La Jolla, CA

Anne E. Fung, MD
California Pacific Medical Center
Pacific Eye Associates
San Francisco, CA

Ninel Z. Gregori, MD
Associate Professor of Clinical Ophthalmology
Bascom Palmer Eye Institute
University of Miami Miller School of Medicine
Miami, FL

Gregory S. Hageman, PhD
John A. Moran Presidential Professor
Executive Director, Moran Center for Translational Medicine
John A. Moran Eye Center
University of Utah
Salt Lake City, UT

Jeffrey S. Heier, MD
Director, Vitreo-Retina Service
Ophthalmic Consultants of Boston
Boston, MA

David R. Hinton, MD, FARVO
Professor of Pathology and Ophthalmology
Gavin S. Herbert Professor of Retinal Research
Associate Dean of Vision Science
Vice Chair, Department of Pathology
Keck School of Medicine
University of Southern California
Los Angeles, CA
Mandarin Oriental, Miami is one of America’s finest hotels and recently awarded the AAA Five Diamond Award. Ideally located on prestigious Brickell Key, its deluxe, waterfront location perfectly blends the opulence you’ll find within. The rooms are luxurious, the award-winning restaurants are some of the finest in Miami and the spa is one of the most beautiful in the world. The hotel's extensive leisure facilities make it the perfect choice for a conference or a holiday in Miami.

HOTEL RESERVATIONS
For hotel information and reservations, please call (305) 913-8282 or (800) 526-6566. The special hotel rate for conference attendees is $379 per night for single or double plus tax. Mandarin Oriental, Miami will extend the special group rate for three days prior and three days after the main program dates, subject to availability. Check-in time is 3:00 pm; Check-out time is 12:00 noon.

CANCELLATION POLICY
Conference tuition, less $100 cancellation fee, is refundable if notice is received on or before January 8, 2014. Cancellations received on or after January 9, 2014 will not be refunded.

CONFERENCE FEES
Registration fee is $425. Registration fees include course materials, opening reception continental breakfast, lunch and refreshment breaks. Conference fees do not include hotel accommodations. For hotel cancellation policies, please contact the Mandarin Oriental Miami. Additional information visit: www.mandarinoriental.com/miami.
ACCREDITATION
University of Miami Leonard M. Miller School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION
The University of Miami Leonard M. Miller School of Medicine designates this live activity for a maximum of 9.25 AMA PRA Category 1 Credits.™ Physicians should claim only the credit commensurate with the extent of their participation in the activity.

DISCLOSURE AND CONFLICT OF INTEREST RESOLUTION
All conflicts of interest of any individual in a position to control the content of this CME activity will be identified and resolved prior to this educational activity being provided. Disclosure about provider and faculty relationships, or the lack thereof, will be provided to learners.

SERVICES FOR THE DISABLED
If special arrangements are required for an individual with a disability to attend this conference, please contact Karen Davila at (305) 326-6110 on or before January 15, 2014.

REGISTRATION
Space is limited. Please register early.
To register by mail: Please complete the registration form and return with your check or credit card payment to: Bascom Palmer Eye Institute Department of Continuing Medical Education 1120 NW 14th Street, Suite 1558, Miami, FL 33136 (Att: Karen Davila)
To register by fax: Please complete the registration form and return with your credit card payment to (305) 326-6518.

For more information contact:
Bascom Palmer Eye Institute Department of Continuing Medical Education at (305) 326-6110 / Email: bascompalmercme@miami.edu